What is the 13F Pro Quality Score for PMVP?

13F Pro ranks PMV Pharmaceuticals, Inc. (PMVP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PMVP's current score at https://13fpro.ai/research/PMVP (free sign-up required for the full ranking).

Where does 13F Pro source PMVP data?

All PMV Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. PMV Pharmaceuticals, Inc. files with the SEC under CIK 1699382. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PMVP in?

PMV Pharmaceuticals, Inc. (PMVP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PMVP research updated on 13F Pro?

PMVP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PMV Pharmaceuticals, Inc.(PMVP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1699382 PMVP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PMVP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PMV Pharmaceuticals, Inc. (PMVP), a Healthcare sector company. PMVP is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), PMV Pharmaceuticals, Inc. reports net income of $-18.0M, free cash flow of $-19.7M. Top institutional holders of PMVP by reported 13-F value include BML Capital Management,, TANG CAPITAL MANAGEMENT, Sio Capital Management,, based on the most recent SEC filings. PMVP trades on the Nasdaq exchange and files with the SEC under CIK 1699382. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PMVP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PMV Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-18.0M

Free Cash Flow

Q1 2026

$-19.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+19.9% YoY

$-58.7MFY 2024

FY20 $-34.4MFY21 $-57.8MFY22 $-73.3MFY24 $-58.7M

Operating Income

-10.9% YoY

$-85.4MFY 2024

FY20 $-34.9MFY21 $-58.3MFY22 $-77.0MFY24 $-85.4M

EPS (Diluted)

+29.2% YoY

$-1.14FY 2024

FY20 $-2.40FY21 $-1.28FY22 $-1.61FY24 $-1.14

Total Assets

-29.2% YoY

$191.3MFY 2024

FY20 $365.5MFY21 $331.6MFY22 $270.3MFY24 $191.3M

Op. Cash Flow

+19.6% YoY

$-51.3MFY 2024

FY20 $-32.7MFY21 $-46.6MFY22 $-63.8MFY24 $-51.3M

Metric	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Net Income	$-58.7M +19.9%	$-73.3M -26.7%	$-57.8M -68.0%	$-34.4M -35.8%	$-25.4M -44.6%	$-17.5M
Operating Income	$-85.4M -10.9%	$-77.0M -32.2%	$-58.3M -66.8%	$-34.9M -31.2%	$-26.6M -41.0%	$-18.9M
EPS (Diluted)	$-1.14 +29.2%	$-1.61 -25.8%	$-1.28 +46.7%	$-2.40	—	—
Total Assets	$191.3M -29.2%	$270.3M -18.5%	$331.6M -9.3%	$365.5M +254.8%	$103.0M	—
Operating Cash Flow	$-51.3M +19.6%	$-63.8M -36.9%	$-46.6M -42.2%	$-32.7M -48.4%	$-22.1M -45.4%	$-15.2M

AI Insight: PMVP Financial Trends

PMV is burning cash at a steady ~$18–23M quarterly rate with no revenue, eroding equity from $214M to $88M over two years.

• Operating losses stabilized at $19–23M per quarter since Q3 2024; Q4 2025 and Q1 2026 show slight improvement to $19M and $19M respectively.

• Equity declined 59% from Q2 2024 ($214M) to Q1 2026 ($88M), driven by consistent net losses and zero revenue generation.

• Operating cash burn remained elevated at $17–20M per quarter with no material change in trajectory across eight quarters.

⚠ Equity runway now ~$88M at current burn rate; company has approximately 4–5 quarters of cash remaining without revenue inflection.

⚠ Zero revenue across entire period signals preclinical/early-stage pipeline with no near-term commercialization catalyst visible in financials.

AI Insight: PMVP Ratio Trends

PMV Pharmaceuticals has deteriorated sharply across all return metrics, with Q1 2026 ROE at -82.0% and ROIC at -86.5%, marking the worst performance in the dataset.

• ROE collapsed from -2.3% in Q2 2024 to -82.0% in Q1 2026, a 79.7pp decline. ROIC fell from -37.6% to -86.5% over same period.

• TTM ROE and ROA both reached -89.1% and -81.1% respectively, indicating sustained negative earnings generation across trailing twelve months.

⚠ ROIC deteriorated 12.1pp from Q4 2025 (-73.5%) to Q1 2026 (-86.5%), signaling acceleration of value destruction in latest quarter.

⚠ No operating margin, net profit margin, or debt/equity data available; unable to assess cost structure or leverage trajectory.

Get alerted when PMVP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PMV Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PMVP

BML Capital Management, LLC
$6.6M5,320,000 sh
TANG CAPITAL MANAGEMENT LLC
$5.3M4,245,085 sh
Sio Capital Management, LLC
$3.8M3,076,580 sh
ArrowMark Colorado Holdings LLC
$3.6M2,872,764 sh
Euclidean Capital LLC
$3.3M2,627,643 sh
Eversept Partners, LP
$2.9M2,348,360 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.4M1,974,906 sh
TWO SIGMA INVESTMENTS, LP
$2.3M1,884,530 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$2.3M1,860,000 sh
BlackRock, Inc.
$1.1M874,374 sh

Fund	Value	Shares
BML Capital Management, LLC	$6.6M	5,320,000
TANG CAPITAL MANAGEMENT LLC	$5.3M	4,245,085
Sio Capital Management, LLC	$3.8M	3,076,580
ArrowMark Colorado Holdings LLC	$3.6M	2,872,764
Euclidean Capital LLC	$3.3M	2,627,643
Eversept Partners, LP	$2.9M	2,348,360
VANGUARD CAPITAL MANAGEMENT LLC	$2.4M	1,974,906
TWO SIGMA INVESTMENTS, LP	$2.3M	1,884,530
ADAGE CAPITAL PARTNERS GP, L.L.C.	$2.3M	1,860,000
BlackRock, Inc.	$1.1M	874,374

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PMVP on your watchlist

Track score changes the day PMV Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PMVP a good stock to buy?

13F Pro's AI-powered analysis of PMV Pharmaceuticals, Inc. (PMVP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PMVP are available on the PMVP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PMVP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PMVP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PMV Pharmaceuticals, Inc.'s investment landscape.